Argus analyst David Toung raised the firm’s price target on AmerisourceBergen to $190 from $170 and keeps a Buy rating on the shares. The company’s key growth drivers in 2023 are expected to be in biosimilars, specialty and oncology therapies, and capital deployment for M&A, the analyst tells investors in a research note. Toung adds that the AmerisourceBergen guidance for 2023 reflects the anticipated strong performance of the U.S. Healthcare Solutions distribution business, though he also lowers his FY23 EPS view by 25c to $11.55 due to headwinds to the international business from the unfavorable impact of foreign exchange.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABC:
- AmerisourceBergen price target raised to $199 from $195 at Baird
- Billionaire Leon Cooperman Says the Bear Market Is Expected to Continue in 2023 — Here Are 2 ‘Safe Haven’ Stocks That Analysts Like
- DOJ suit shouldn’t create meaningful overhang for AmerisourceBergen, says BofA
- AmerisourceBergen calls DOJ complaint ‘an attempt to shift blame’ from DEA
- The Justice Department Sues AmerisourceBergen (NYSE:ABC). Here’s Why
